Last $10.40 USD
Change Today +0.12 / 1.17%
Volume 513.5K
RMTI On Other Exchanges
Symbol
Exchange
RMTI is not on other exchanges.
As of 8:10 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

rockwell medical inc (RMTI) Snapshot

Open
$10.23
Previous Close
$10.28
Day High
$10.45
Day Low
$10.10
52 Week High
03/10/14 - $14.80
52 Week Low
12/10/14 - $8.10
Market Cap
523.6M
Average Volume 10 Days
791.7K
EPS TTM
$-0.52
Shares Outstanding
50.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ROCKWELL MEDICAL INC (RMTI)

Related News

No related news articles were found.

rockwell medical inc (RMTI) Related Businessweek News

No Related Businessweek News Found

rockwell medical inc (RMTI) Details

Rockwell Medical, Inc. operates as an integrated biopharmaceutical company in the United States and internationally. It offers products and services for the treatment of end-stage renal disease, chronic kidney disease (CKD), iron deficiency, secondary hyperparathyroidism, and hemodialysis. The company’s products are used to cleanse patients' blood and replace nutrients lost during the kidney dialysis process. Its lead drug candidates include Triferic, which is in late-stage clinical development for the treatment of iron replacement in dialysis patients; and Calcitriol, a generic active vitamin D for the treatment of secondary hyperparathyroidism in dialysis patients. The company also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric-acid concentrate, Dri-Sate dry acid, Renal Pure liquid acid concentrate, dry acid concentrate mixing system, RenalPure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Rockwell Medical, Inc. sells its products directly to hemodialysis providers, as well as through independent sales agents and distributors. The company was founded in 1995 and is based in Wixom, Michigan.

rockwell medical inc (RMTI) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $941.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $456.3K
Chief Medical Officer
Total Annual Compensation: $499.8K
Chief Scientific Officer and Member of Scient...
Total Annual Compensation: $529.5K
Compensation as of Fiscal Year 2013.

rockwell medical inc (RMTI) Key Developments

Rockwell Medical, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Rockwell Medical, Inc. reported consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported sales of $14,447,653 compared to $13,964,624 for the last year. Operating loss was $5,020,811 compared to $7,529,010 for the last year. Loss before income taxes was $6,383,647 compared to $8,332,105 for the last year. Net loss was $6.3 million or $0.14 per basic and diluted share compared to $8.3 million or $0.21 per basic and diluted share in the fourth quarter of 2013. For the year, the company reported sales of $54,188,444 compared to $52,379,543 for the last year. Operating loss was $17,559,101 compared to $47,059,266 for the last year. Loss before income taxes was $21,327,157 compared to $48,783,312 for the last year. Net loss was $21.3 million or $0.52 per basic and diluted share compared to $48.7 million or $1.48 per basic and diluted share in 2013. Cash provided by operating activities was $4,257,778 compared to cash used in operating activities was $50,664,953 for the last year. Purchase of equipment was $684,593 compared to $654,197 for the last year.

Rockwell Medical, Inc., Q4 2014 Earnings Call, Feb 26, 2015

Rockwell Medical, Inc., Q4 2014 Earnings Call, Feb 26, 2015

Rockwell Medical Announces Presentation Schedule for Triferic Clinical Posters at the American Society of Nephrology Meeting November 2014

Rockwell Medical, Inc. announced the presentation schedule for three individual Triferic clinical abstracts selected by ASN's Program Committee for poster presentation at the ASN Kidney Week 2014 Annual Meeting, November 11-16 in Philadelphia, PA. Triferic is the Rockwell's late-stage investigational iron maintenance therapy for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RMTI:US $10.40 USD +0.12

RMTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.01 USD -0.08
Actavis plc $296.14 USD -0.09
AMAG Pharmaceuticals Inc $50.69 USD +1.53
Fresenius Medical Care AG & Co KGaA €74.69 EUR +0.87
View Industry Companies
 

Industry Analysis

RMTI

Industry Average

Valuation RMTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.7x
Price/Book 7.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCKWELL MEDICAL INC, please visit www.rockwellmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.